Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Zevra Therapeutics (ZVRA) over the last 7 years, with Q3 2025 value amounting to -$1.4 million.

  • Zevra Therapeutics' Change in Receivables fell 1745.89% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 48975.2%. This contributed to the annual value of -$6.9 million for FY2024, which is 17565.54% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Change in Receivables of -$1.4 million as of Q3 2025, which was down 1745.89% from $4.9 million recorded in Q2 2025.
  • Zevra Therapeutics' Change in Receivables' 5-year high stood at $8.7 million during Q1 2021, with a 5-year trough of -$9.4 million in Q2 2021.
  • Over the past 5 years, Zevra Therapeutics' median Change in Receivables value was $642000.0 (recorded in 2024), while the average stood at $712684.2.
  • In the last 5 years, Zevra Therapeutics' Change in Receivables crashed by 537674.42% in 2021 and then skyrocketed by 243626.37% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Change in Receivables (Quarter) stood at -$91000.0 in 2021, then skyrocketed by 2436.26% to $2.1 million in 2022, then skyrocketed by 250.42% to $7.4 million in 2023, then plummeted by 63.5% to $2.7 million in 2024, then plummeted by 149.98% to -$1.4 million in 2025.
  • Its Change in Receivables stands at -$1.4 million for Q3 2025, versus $4.9 million for Q2 2025 and $2.1 million for Q1 2025.